A pivotal Phase III trial with firibastat in resistant hypertension
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Firibastat (Primary)
- Indications Resistant hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Quantum Genomics
- 17 Jan 2019 According to a Quantum Genomics media release, the steering committee includes Keith C. Ferdinand, William B. White and Jacques Blacher.
- 17 Jan 2019 According to a Quantum Genomics media release, the company is preparing to launch this trial, thus paving the way for marketing authorisation.
- 17 Jan 2019 According to a Quantum Genomics media release, the company has announced the appointment of the steering committee for this pivotal trial.The steering committee will work closely with Quantum Genomics scientific team to define the design of this trial, in particular its methodology, target population and evaluation criteria, and will be involved in discussions with the EMA and FDA.It will also be directly involved in this trials conduct.